We are BioCanCell, a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies to treat cancer in areas of unmet need.
Focus on discovering and developing therapies for patients with cancer in areas of unmet need
Initial program: genetic therapy for early stage bladder cancer
Utilizes technology licensed from Hebrew University
Founded in 2004; based in Cambridge and Jerusalem
New CEO (former Harvard faculty; Ariad chief medical officer) based in Cambridge, building U.S. team and infrastructure
$22 million (end Q2 2017)
Approximate market capitalization
Publicly traded in Israel (TASE:BICL)
$5 million (end Q2 2017)
cash, no debt
Our initial program is the genetic therapy for early stage bladder cancer. BC-819, our most advanced investigational agent, is under development as a treatment for non-muscle-invasive bladder cancer (NMIBC). BC-819 has been tested in three clinical trials to date, and two registrational trials are set to be initiated in 2017 and will begin enrolling patients in the first half of 2018.
We are located in Cambridge, MA, and in Jerusalem, and are publicly traded on the Tel Aviv Stock Exchange (TASE:BICL).
Our R&D activities build upon the research of Professor Abraham Hochberg of the Hebrew University of Jerusalem. Professor Hochberg isolated the human H19 gene and determined that the gene is expressed in over forty different forms of cancer, while being quiescent in normal adult tissues. H19-based therapy combines a highly selective method of killing cancer cells with a favorable safety profile. Each of our product candidates relies on a proprietary H19 technology platform, with the potential to provide benefits that are competitive with existing cancer treatment methods.
We are dedicated to the discovery, development and commercialization of effective and safe treatments for cancer that address significant unmet medical needs and provide clinical benefits to millions of patients worldwide.